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Health information exchange (HIE) initiatives are in various stages of development across the United States. They aim to bring pre-
viously unavailable clinical data from patients’ disparate health records, which may be spread over multiple provider and payer net-
works, to the point of care where clinicians and their patients need it most. The implications of these initiatives on public health are
numerous. This article provides general evaluation methods for measuring the impact of HIE on public health in six use cases: (1) man-
dated reporting of laboratory diagnoses, (2) mandated reporting of physician-based diagnoses, (3) public health investigation, (4) disease-
based non-reportable laboratory data, (5) antibiotic-resistant organism surveillance, and (6) population-level quality monitoring.
 2007 Elsevier Inc. All rights reserved.
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The potential of health information exchange (HIE) to
improve the public health and public health activities
may seem obvious, but current literature provides little evi-
dence proving these eﬀects. More than 165 regional health
information organizations (RHIOs) in 49 states nationwide
are developing HIE in one form or another [1] and, there-
fore, the volume of HIE data that could be used for public
health purposes is substantial. There are a number of pub-
lic health use cases for HIE [2], but only a few have been
implemented [3–5], and even fewer formally evaluated.
Those that have been implemented mainly use proprietary
data feeds directly from individual hospitals and other data
providers instead of data directed to them through a clini-
cal HIE implementation, often because a functional HIE
network is not yet available.
This paper will: (1) describe some of the potential public
health use cases for HIE as described by Mostashari et al.
[2] and (2) discuss potential approaches to the evaluation of1532-0464/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2007.08.003
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E-mail address: jason.shapiro@dbmi.columbia.eduthese use cases. Because RHIOs and HIE vary widely in
their own use cases and implementations, it is diﬃcult to
create speciﬁc evaluation recommendations. The approaches
to evaluation of public health uses of HIE described here
will be of a general nature; this chapter will discuss
methods and metrics when they may be more easily
generalized across varying public health HIE scenarios.2. Public health use cases
2.1. Mandated reporting of laboratory diagnoses
2.1.1. Description of use case
This use case describes the situation where a reportable
disease may be identiﬁed through laboratory results. States
specify diseases requiring mandated reporting, which usu-
ally includes such diseases as tuberculosis, gonorrhea and
viral hepatitis [6]. Electronic laboratory reporting directly
to health departments has been shown to improve the time-
liness and completeness of reporting [7,8]. Despite this
demonstrated beneﬁt, laboratories and health departments
have been slow to adopt electronic laboratory reporting
because of the diﬃculty of mapping disparate systems
ed to DOHg
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projects create these mappings for clinical exchange, HIE
could enable or greatly enhance a region’s ability to elec-
tronically transmit reportable disease data to the appropri-
ate agency and may increase the eﬃciency and quality of
public health surveillance, particularly for high-volume
diseases.
2.1.2. Approaches to evaluation
Measuring the volume of relevant data transmitted
would be a primary measure of success in this use case
(i.e. recall):
frelevantg \ fretrievedg
frelevantg
If feasible, a before–after study could be conducted to
demonstrate any change in the frequency of mandated
reporting of laboratory diagnoses using HIE laboratory
data. The study could be limited to a particular disease that
might be easy to measure in the pre-implementation phase,
such as tuberculosis (TB). The study would consider the
number of positive TB cultures from the participating
HIE data providers (i.e. hospitals), the number of these
cases that were reported to the health department both
pre- and post-implementation, and the length of time it
took these cases to be reported. In this case the metric
would be:
fAll TB pos cultures from stakeholderg \ fTB cases report
fAll TB pos cultures from stakeholderg
Additional metrics of interest could look at changes in
eﬃciency, completeness and timeliness of reporting.
2.2. Mandated reporting of physician-based diagnoses
2.2.1. Description of use case
Physicians are obligated to independently report to the
health department the same disease described above in the
ﬁrst use case so that additional clinical (e.g. date of onset)
or risk factor (e.g. occupation, travel) information can be
gained. Physician compliance with this requirement is
highly variable (10–85%) [10]. HIE systems may use diag-
nosis codes (i.e. ICD9-CM), procedure codes (CPT), or
medications to identify cases that would otherwise have
gone unreported. This automatic screening for certain
data through the HIE would likely require manual review
to ﬁlter out erroneous or non-relevant cases (i.e. diagnoses
of rule-out TB with results that are negative for TB)
before being reported to the health department. As HIE
systems mature and begin to incorporate more informa-
tion (e.g. complete clinical notes from an electronic health
record (EHR)), this use case may employ more advanced
informatics functions, such as natural language process-
ing, data mining, or use of knowledge bases, to screen
the entire record for relevant cases and improve system
recall.2.2.2. Approaches to evaluation
Recall would be diﬃcult to measure in this use case since
measuring all relevant cases for the denominator would be
time consuming and expensive, likely requiring a chart
review instrument and expert reviewers to serve as a gold
standard. Another measure of interest is to evaluate the
performance of the system (i.e. the precision):
frelevantg \ fretrievedg
frelevantg
Precision gives an idea of how well the system is per-
forming in terms of the number of erroneous or non-rele-
vant cases that are included. Measurement of precision
would require a log ﬁle capturing all potential clinician-
reportable diseases detected by the system, followed by
manual review to determine which cases are relevant. An
example of this metric using the TB example would be:
fTB pos culturesg \ fcases detected by systemg
fAll cases detected by systemg
Another useful evaluative measure might be to deter-
mine the volume of reporting pre- and post-implementa-
tion in much the same way that was suggested above
for mandated reporting of laboratory diagnoses, as well
as the eﬃciency, completeness and timeliness of
reporting.2.3. Public health investigation
2.3.1. Description of use case
In this instance, the department of health is already
aware of a reportable disease or other case requiring addi-
tional investigation and in possession of full patient identi-
ﬁers. Traditionally these additional investigations required
multiple telephone calls, travel, and requests for paper
records in order to conduct the investigation. With the
advent of HIE, the health department investigator simply
becomes another user of the HIE system and queries the
system for additional information on the patient in ques-
tion, potentially decreasing the amount of time and eﬀort
necessary to complete the required investigation.
2.3.2. Approaches to evaluation
Because implementation of this use case will vary
depending on the extent to which the HIE incorporates
clinical data, and the scope and granularity of that data
(e.g. does the HIE give access to the full electronic health
record, or does it only provide results retrieval?), recom-
mendation of a speciﬁc evaluation is diﬃcult. One possibil-
ity is to do a qualitative or semi-qualitative study of the
public health investigator’s experience through surveys,
semi-structured interviews or observational techniques.
This would allow the evaluators to determine if the HIE
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health department needs when conducting investigations.
On the surface, this is more of an implementation-level
evaluation to determine if an individual project is success-
ful, but if this were done across multiple HIE projects,
analysis might permit the development of a set of standard
practices for HIE implementations to help identify the data
elements and user interface features that are most essential
to this use case.
2.4. Disease-based non-reportable laboratory data
2.4.1. Description of use case
Other diseases are of interest for biosurveillance but are
not often on the list for mandated reporting (e.g. inﬂuenza,
respiratory syncitial virus, norovirus, rotavirus). Some lab-
oratories are already gathering data on these pathogens
[11], but the use of HIE systems would help consolidate
these data and make them more accessible to health depart-
ments. Although these cases will not require public health
action on an individual basis, knowledge of the disease pat-
terns in the community can help guide public health mes-
sages and rule-out less innocuous epidemiological causes.
2.4.2. Approaches to evaluation
Because this use case will rely on the development of fas-
ter, less expensive, and more accessible assays to clinicians,
and these are being developed and deployed in parallel with
HIE systems, they will likely act as a confounder, making it
diﬃcult to construct an evaluation plan that incorporates a
pre-implementation phase. Of most interest here is the
gathering and analysis of empirical data to make new dis-
coveries regarding the epidemiology of these common
pathogens.
2.5. Antibiotic-resistant organism surveillance
2.5.1. Description of use case
In this use case, microbiology culture resistance pat-
terns from would be sent through the HIE system directly
to the health department, and could be used to construct
community-wide antibiograms that help focus antibiotic
selection based on local resistance patterns. Additionally,
this system could be used to notify clinicians when a
patient with a previously diagnosed antibiotic-resistant
organism (ARO) presents [12], which can decrease the
spread of AROs among hospitalized patients as much as
16-fold [13]. This also potentially aﬀects the ﬁnancial eval-
uation of an HIE implementation since the cost of hospi-
tal-acquired antibiotic-resistant infections may be as high
as $27,083 [14].
2.5.2. Approaches to evaluation
A study evaluating the rates of local antibiotic resistance
patterns before and after the implementation of a commu-
nity-wide antibiogram would be of interest. Since the inter-
vention here is the dissemination of a community-wideantibiogram, measurement could be done electronically
both pre- and post-intervention as long as the HIE system
is in place and can provide the required data. Similarly,
studies could be done pre- and post-implementation on a
hospital level to see if an ARO notiﬁcation system leads
to earlier identiﬁcation and isolation of ARO-infected
patients, and to see if hospital rates of nosocomial ARO
infections decrease.
2.6. Population-level quality monitoring
2.6.1. Description of use case
There has been mounting concern over the growing epi-
demics of chronic diseases (diabetes, heart disease), and
public health has become increasingly involved in cam-
paigns aimed at their prevention (secondary prevention)
and the prevention of their sequelae (tertiary prevention).
Although the quality of preventative care is known to be
poor [15], monitoring on a community-wide level across
diﬀerent providers and payers has proved very diﬃcult.
To the extent that an HIE system transcends the barriers
of institutionally ‘‘siloed’’ data, the HIE might be able to
provide an enhanced ability to monitor quality metrics
across an entire community for these diseases (e.g. rates
of colonoscopy or mammograms for cancer screening, or
hemoglobin A1C levels for diabetes control).
2.6.2. Approaches to evaluation
Again, this use case would require a pre- and post-
implementation study. A number of organizations have
developed, or are developing, standard sets of quality mea-
sures that could be used for evaluation [16]. Quality mea-
sures in an ambulatory care setting are typically
organized by disease category, often following the twenty
priority areas deﬁned by the Institute of Medicine [17]
and reﬂected in Healthy People 2010 (U.S. Department
of Health and Human Services, 2000) and Take Care
New York [18]. Any of these quality measures would need
to be evaluated for each HIE implementation (i.e. are the
data available) and target diseases that the local health
department wants to monitor.
3. Conclusion
This paper describes preliminary suggestions for mea-
suring the impact of HIE on public health in speciﬁc use
cases. There are other secondary and tertiary beneﬁts to
improved public health that would be much more diﬃcult
to measure. If these HIE systems do improve quality and
safety, while reducing costs and improving patient and pro-
vider satisfaction as many believe, then the overall health
of the population will improve. In turn, this will lead to
fewer lost wages and decreases in productivity due to illness
or disability, resources will be freed for use in other areas,
and an overall improved health should follow. These kinds
of global improvements are diﬃcult or impossible to
measure.
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HIE, while projects are amassing stakeholders and building
infrastructure, the projects will be limited in scope due to
only partial penetration of local markets and therefore only
partial data capture (recall). Measures likely to be aﬀected
during this early phase are eﬃciency measures (decreased
duplicate testing, decreased admissions and decreased
length of stay) and costs (monetization of the eﬃciency
measures listed above and monetization of safety or quality
measures such as decreased that may be detected early such
as decreased adverse drug events or decreased nosocomial
infections). These early measures may be used to calculate
a return on investment of the initial implementation costs,
and to make the argument to fund ongoing operational
support for these HIE systems.
As these HIE systems mature and begin to share data
with one another, and a truly interoperable nationwide
health information network (NHIN) begins to coalesce,
quality and safety eﬀects will begin to accrue and be mea-
surable. As the safety and quality of care improves, there
will likely be synergies between the increased levels of infor-
mation available and improved services that can be layered
on top of the NHIN backbone (e.g. clinical decision sup-
port that employs knowledge of a patient’s comprehensive
medical history, medication lists based on claims and pre-
scription ﬁll data from payers and pharmacies, or pharma-
covigilance that allows surveillance for adverse aﬀects of
new medications that were not detected in late-phase clin-
ical trials). This will lead to a general improvement in pop-
ulation health and will likely be very diﬃcult to accurately
measure or monetize.Acknowledgments
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